Sarepta shares surge after surprise approval of Duchenne Muscular Dystrophy drug

Shares of Sarepta Therapeutics Inc soared 36% on Friday after U.S. regulators shocked Wall Street by approving the company's treatment for a muscle-wasting disorder less than four months after rejecting the drug over safety concerns.